LUNG-MAP
A lung cancer precision medicine trial

VOLUME 14 | FALL 2020 NEWSLETTER WWW.LUNG-MAP.ORG

A New Sub-Study Is On The Way

Lung-MAP has a new treatment option coming, with a target activation date in December 2020.

It's **S1900E**, "A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)."

This study will help shed new light on whether the presence of co-mutations affects response to the KRAS G12C inhibitor AMG 510.

Study chairs **Sukhmani Padda, MD**, of Stanford Health Care and **David E. Gerber, MD**, of UT Southwestern Medical Center say:

"In recent years, KRAS mutated non-small cell lung cancer has emerged as a heterogeneous disease based on co-mutations such as STK11 and TP53. Response to treatments may vary depending on the presence of these co-mutations. The Lung-MAP S1900E sub-study will provide early and important insights into how these KRAS molecular subtypes may affect response to direct KRAS G12C inhibitors."



Padda

Gerber

Learn More by Joining Our Webinar

The Lung-MAP team is holding a training and study update webinar on October 26th from 9:15-10:45 PT / 11:15-12:45 CT / 12:15-1:45 ET

Topics will include:

- A training overview of S1900E
- Lung-MAP logistics refresher
- Tips from our Site Coordinators Committee for conducting the trial during COVID-19
- Update on translational medicine and publications
- Q&A session

Register here.

We have a WebEx capacity of 100 lines. If multiple people at your site attend, please join together if possible.

To receive training credit, please enter your CTEP Institution ID(s) (i.e. IA123) in the "Address 1" field on the registration form.

Thank You for Registering Patients!

As of 10/8/20, Lung-MAP has logged: **1646** screening registrations | **862** sub-study assignments | **237** sub-study registrations

LEARN MORE AT
WWW.LUNG-MAP.ORG

NCI National Clinical Trials Network | SWOG CANCER RESEARCH NETWORK | FNIH Foundation for the National Institutes of Health | FRIENDS of CANCER RESEARCH

LUNG-MAP

A lung cancer precision medicine trial

Active Sub-Studies:

1. S1800A A Phase II Randomized Study of Ramucirumab plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Updated accrual goal: Approximately 155

Primary Objective: Compare overall survival between patients previously treated with platinum-based chemotherapy and immunotherapy for Stage IV or recurrent non-small lung cancer randomized to ramucirumab and MK-3475 (pembrolizumab) versus standard of care.

Note: *Study is estimated to close mid-November 2020.*

2. S1900A A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Accrual goal: 88

Primary Objective: Evaluate the response rate associated with rucaparib in patients with genomic loss of heterozygosity high and/or deleterious BRCA 1/2 mutation-positive non-small cell lung cancer. A biomarker-driven study for patients with Stage IV or recurrent non-small cell lung cancer.

Note: *Cohorts 1 and 2 (squamous and non-squamous) are temporarily closed to let data mature for interim analysis.*

3. S1900B A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Accrual goal: 124

Primary Objective: Evaluate the response rate to LOXO-292 – a novel, highly selective, ATP-competitive small molecule RET inhibitor – in patients with previously treated stage IV or recurrent RET fusion-positive non-small cell lung cancer.

Note: *Because RET fusions are very rare, this sub-study allows patients with documented RET fusions detected outside of Lung-MAP to use these results to participate in S1900B.*

4. S1900C A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)

Accrual goal: 44

Primary Objective: Evaluate the response rate with the PARP inhibitor talazoparib plus the monoclonal antibody anti-PD-L1 inhibitor avelumab in patients with Stage IV or recurrent, non-squamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations who were previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.

TOP ACCRUING SITES

1.	UPMC Hillman Cancer Center	Pittsburgh, PA	**89**
2.	Wilmot Cancer Center	Rochester, NY	**30**
3.	Mercy Medical Center	Canton, OH	**29**
4.	Missouri Baptist Medical Center	St. Louis, MO	**27**
5.	Stephenson Cancer Center	Oklahoma City, OK	**24**
6.	Good Samaritan Hospital	Cincinnati, OH	**23**
7.	UK Markey Cancer Center	Lexington, KY	**22**
7.	Essentia Health	Duluth, MN	**22**
7.	UNM Comprehensive Cancer Center	Albuquerque, NM	**22**
8.	Northside Hospital Cancer Institute	Atlanta, GA	**21**
9.	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago, IL	**20**
10.	Roswell Park Comprehensive Cancer Center	Buffalo, NY	**18**
10.	VA Connecticut Healthcare System	West Haven, CT	**18**

Data reflects trial activity as of 10/9/2020

CONTACT US

Protocol & Regulatory Questions
protocols@swog.org

Eligibility & Data Submission Questions
LUNGMAPQuestion@crab.org

General Medical Questions
LUNGMAP@swog.org

S1800A Medical Questions
S1800AMedicalQuery@swog.org

S1900A Medical Questions
S1900AMedicalQuery@swog.org

S1900B Medical Questions
S1990BMedicalQuery@swog.org

S1900C Medical Questions
S1900CMedicalQuery@swog.org

Central Monitoring Questions
centralmonitorquestion@crab.org

Quality Assurance Auditing Questions
qamail@swog.org